Landau Lab collaborates with Carisma Therapeutics!
- landaulabnyu
- Aug 25, 2020
- 1 min read
Updated: Nov 7, 2020
CARISMA Therapeutics Inc. now shares the license to use the vpx lentiviral vector created in our lab to facilitate the development of chimeric antigen receptor macrophages (CAR-M) targeting human epidermal growth factor receptor 2 (HER2), for the treatment of solid tumors.
Check out the official press release here.